Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Change in Cash (2016 - 2025)

Lisata Therapeutics' Change in Cash history spans 13 years, with the latest figure at -$3.0 million for Q4 2025.

  • For Q4 2025, Change in Cash rose 7.82% year-over-year to -$3.0 million; the TTM value through Dec 2025 reached -$253000.0, up 96.04%, while the annual FY2025 figure was -$253000.0, 96.04% up from the prior year.
  • Change in Cash reached -$3.0 million in Q4 2025 per LSTA's latest filing, down from $2.2 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $8.7 million in Q3 2023 to a low of -$9.8 million in Q4 2023.
  • Average Change in Cash over 3 years is -$1.3 million, with a median of -$3.2 million recorded in 2024.
  • Peak YoY movement for Change in Cash: crashed 200.53% in 2024, then skyrocketed 608.63% in 2025.
  • A 3-year view of Change in Cash shows it stood at -$9.8 million in 2023, then soared by 66.45% to -$3.3 million in 2024, then rose by 7.82% to -$3.0 million in 2025.
  • Per Business Quant, the three most recent readings for LSTA's Change in Cash are -$3.0 million (Q4 2025), $2.2 million (Q3 2025), and -$3.4 million (Q2 2025).